BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32968751)

  • 21. Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
    Hassani S; Khaleghian A; Ahmadian S; Alizadeh S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Ann Hematol; 2018 Jan; 97(1):83-93. PubMed ID: 29159499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.
    Bashash D; Ghaffari SH; Zaker F; Kazerani M; Hezave K; Hassani S; Rostami M; Alimoghaddam K; Ghavamzadeh A
    Anticancer Agents Med Chem; 2013 Sep; 13(7):1115-25. PubMed ID: 23293885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
    Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
    Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular targets of arsenic trioxide in malignant cells.
    Miller WH
    Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arsenic trioxide: mechanisms of action.
    Davison K; Mann KK; Miller WH
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):3-7. PubMed ID: 12012315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
    Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
    Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'AngiĆ² A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
    Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide.
    Miller KP; Venkataraman G; Gocke CD; Batista DA; Borowitz MJ; Burns KH; Pratz K; Duffield AS
    Am J Clin Pathol; 2019 Oct; 152(5):675-685. PubMed ID: 31305869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
    Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
    Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
    Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
    Lee C; Lin Y; Huang M; Lin C; Liu C; Chow J; Liu HE
    Leuk Lymphoma; 2006 Mar; 47(3):521-9. PubMed ID: 16396776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts.
    Iriyama N; Yuan B; Yoshino Y; Hatta Y; Horikoshi A; Aizawa S; Takeuchi J; Toyoda H
    Oncol Rep; 2013 Jun; 29(6):2362-8. PubMed ID: 23563754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis].
    Nagao R; Hosoba R; Yahagi Y; Gunji T; Uryu H; Hattori D; Momoki M; Yamazaki H
    Rinsho Ketsueki; 2019; 60(10):1431-1435. PubMed ID: 31695003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
    Freyer CW; Peterson CE; Man Y; Przespolewski A; Baron J; Luger SM
    Leuk Lymphoma; 2021 Mar; 62(3):696-702. PubMed ID: 33106056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arsenic trioxide: an ancient drug revived.
    Zhou J
    Chin Med J (Engl); 2012 Oct; 125(19):3556-60. PubMed ID: 23044323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
    Firkin F; Roncolato F; Ho WK
    Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis.
    Safa M; Mousavizadeh K; Noori S; Pourfathollah A; Zand H
    Eur J Pharmacol; 2014 Aug; 736():115-23. PubMed ID: 24815320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest.
    Hassani S; Ghaffari SH; Zaker F; Mirzaee R; Mardani H; Bashash D; Zekri A; Yousefi M; Zaghal A; Alimoghaddam K; Ghavamzadeh A
    Ann Hematol; 2013 Sep; 92(9):1207-20. PubMed ID: 23645216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
    Takeshita A; Shinjo K; Naito K; Matsui H; Sahara N; Shigeno K; Horii T; Shirai N; Maekawa M; Ohnishi K; Naoe T; Ohno R
    Leukemia; 2005 Aug; 19(8):1306-11. PubMed ID: 15920495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.
    Noh EK; Kim H; Park MJ; Baek JH; Park JH; Cha SJ; Won JH; Min YJ
    Leuk Res; 2010 Nov; 34(11):1501-5. PubMed ID: 20226526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.